Document is current
Any future updates will be listed below
-
Authors
Krill-Burger, J. Michael
Dempster, Joshua M.
Borah, Ashir A.
Paolella, Brenton R.
Root, David E.
Golub, Todd R.
Boehm, Jesse S.
Hahn, William C.
McFarland, James M.
Vazquez, Francisca https://orcid.org/0000-0002-2857-4685
Tsherniak, Aviad
-
Funding
Funding for this research was provided by:
Robertson Foundation
Cancer Dependency Map Consortium
- License Information
-
More Information
Article History
Received: 22 July 2022
Accepted: 21 July 2023
First Online: 23 August 2023
Declarations
:
: Not applicable.
: Not applicable.
: B.R.P. and F.V. receive research support from Novo Ventures. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck, Vir), and is a director of Addgene. T.R.G. receives research funding from Bayer HealthCare, Calico Life Sciences, and Novo Ventures, is a founder and equity holder of Sherlock Biosciences and FORMA Therapeutics, serves a consultant for GlaxoSmithKline, and was formerly a consultant and equity holder in Foundation Medicine acquired by Roche. W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, MPM Capital, KSQ Therapeutics, iTeos, Tyra Biosciences, Frontier Medicine, Jubilant Therapeutics, RAPTTA Therapeutics, Function Oncology, and Calyx. A.T. is a consultant for Cedilla Therapeutics, Foghorn Therapeutics, The Center for Protein Degradation (Deerfield), Tango Therapeutics, and is an SAB member and holds equity in Turbine Simulated Cell Technologies. This work was partially funded by the Cancer Dependency Map Consortium, but no consortium member was involved in or influenced this study.
